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HLA-A, B, C, DRB1, DQB1 matched siblings (29), matched
unrelated donors (22), or unrelated donors mismatched for one
HLA antigen (6), homozygous mismatch (1), one HLA allele (2),
or two HLA alleles (1). Fludarabine 40 mg/m2 was given intra-
venously daily for four days, with each infusion followed imme-
diately by intravenous busulfan. The dose of busulfan for days 1
and 2 was 130 mg/m2. Pharmacokinetic analysis was performed
after the ﬁrst infusion of busulfan; in 59 pts, the goal was to
adjust busulfan doses for days 3 and 4 to achieve an average
targeted Css level of 800-1000 ng/ml. Levels were drawn incor-
rectly in 4 of these pts and doses were not changed. Thirty-ﬁve
(59%) pts had their doses adjusted, increased in 27 and de-
creased in 8, while 20 pts had Css within the desired range
without adjustment. Patients received tacrolimus and standard
doses of methotrexate for GVHD prophylaxis, with the excep-
tion of ﬁve patients. Engraftment occurred in 58 (95%) pts.
Thirty (64%) of 47 pts followed for at least 100 days experi-
enced acute GVHD requiring treatment. Six pts have died of
transplant-related complications and 7 pts have failed to achieve
remission or have relapsed. Median follow-up is 174 days (range
26-448 days). The 100-day K-M estimate of survival for the
whole cohort is 92%, and event-free survival 88%. The 100-day
mortality in this study compares well with the 100-day mortality
reported to the IBMTR for patients with AML, ALL, MDS, and
CML transplanted from either HLA-matched siblings or unre-
lated donors. These preliminary results indicate that tBuFlu is a
promising myeloablative regimen that can be utilized in older
patients with low early treatment-related mortality.
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LACK OF IMMUNE BARRIER TO ALLOGENEIC HEMATOPOIETIC STEM CELL
ENGRAFTMENT IN T, B, AND NK CELL DEFICIENT (RAG2C/B6) MICE
Logronio, K.A.1, Burge, M.2, Shizuru, J.3 1Division of Bone Marrow
Transplant, Stanford University School of Medicine, Palo Alto, CA.
The way that allogeneic hematopoietic stem cells (HSC) resist
engraftment is not completely understood. Natural killer cells
(NK) and lymphocytes are thought to mediate the allograft barrier
in mice that are mismatched at the major histocompatibility com-
plex (MHC). The clearing of niche space is also thought to be
required for donor cell engraftment. Here we attempt to dissect
the relative contribution of these host elements to hematopoietic
resistance using genetically defective Rag2/ (H2b) mice lacking
T and B cells, or Rag2c/ (H2b) mice lacking in T, B, and NK
cells as recipients. We have previously shown that HSCs encounter
greater resistance to engraftment when compared to unfraction-
ated bone marrow (BM), and the resistance can be quantitated by
titrating numbers of HSCs needed to rescue lethally irradiated
recipients. Rescue of syngeneic or CD45 congenic recipients re-
quires only 200 HSCs, whereas higher HSC doses are required as
the genetic disparity increases. In this study, radioresistant MHC-
mismatched AKR/J (H2k) HSCs were transplanted into lethally
irradiated (950 cGy) B6.WT (H2b). All B6.WT mice died of
hematopoietic failure despite attempted rescue with 1000 AKR/J
HSC. No signiﬁcant improvement in engraftment was observed in
Rag2/ mice when compared to B6.WT mice. However, an
impressive difference was noted in the Rag2c/ mice, in which
the immune barrier completely disappeared. A dose of 300 HSC
rescued all irradiated Rag2c/ mice and even 200 AKR HSC, an
amount equivalent to a congenic dose rescued 100% of recipients.
We then sought to determine if engraftment could be achieved
using non-myeloablative conditioning, or no radiation at all.
Rag2c/ recipients of 6000 AKR/J HSCs treated with 500 cGy-
300 cGy resulted in 100% donor engraftment. Additionally, un-
conditioned Rag2c/ also engrafted since 10-20% of donor
AKR/J granulocytes were detected. In contrast, unconditioned
Rag2/ mice showed no evidence of donor cell engraftment. We
also studied the trafﬁcking of allogeneic FVB (H-2q) HSC in
irradiated versus unirradiated Rag2c/ (H-2d) recipients by in
vivo bioluminescence imaging. HSC were observed to enter the
marrow space of irradiated mice within minutes following infusion,
whereas unirradiated mice demonstrated no luciferase signal until
day 5 post-infusion. We conclude that Rag2c/ mice have a
profound reduction in the immune barrier to allogeneic HSC
engraftment and, that in irradiated mice, HSC rapidly enter the
marrow.
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POST-TRANSPLANTATION CYCLOPHOSPHAMIDE (Cy) AS A SINGLE
AGENT FOR GVHD PROPHYLAXIS AFTER HLA MATCHED RELATED AND
UNRELATED BONE MARROW TRANSPLANTATION
Luznik, L., Chen, A., Fuchs, E.J., Phelps, M., Crawford, A.,
Brodsky, R.A., Huff, C.A., Jones, R.J. Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, Baltimore, MD.
In animal models of BMT, a properly timed high dose of Cy
post-BMT selectively eliminates host-versus-graft and graft-ver-
sus-host reactive T cells, thereby preventing graft rejection and
reducing GVHD. We hypothesized that high dose posttransplant
Cy (50 mg/kg IV) administered on days 3 and 4 after BuCy
conditioning may be effective in preventing GVHD and can limit,
or entirely eliminate the need for, standard postgrafting immuno-
suppression. This should lessen immunosuppression and allow
early institution of additional posttransplant immunotherapy such
as DLI. 28 patients with advanced hematologic malignancies were
conditioned with busulfan (PO or IV) on days 7 to 3 and Cy on
days 2 and 1, transplanted with non–T cell–depleted marrow,
and treated with Cy on days 3 and 4 as only postgrafting
immunosuppression. 15 patients (median age 41 years) were al-
lografted with bone marrow from HLA-identical siblings. Time to
neutrophil (	500/l) and platelet (	20000/l, untransfused) en-
graftment was 22 and 31 days, respectively. One patient experi-
enced secondary graft failure and was successfully rescued. Acute
GVHD occurred in 7/15 patients at a median of 43 days after
transplantation (range 20-68 days) and was exclusively grades I (2
patients) and II (5 patients). All 7 patients with GVHD responded
completely to standard therapy (steroids only or steroids  FK-
506) and all of them were successfully rapidly weaned from all
immunosuppressive agents. With a median follow-up of 290 days
(range 50-380), 10/15 patients are alive (all 5 patients died of
relapsed disease) of which 7 are in remission. 13 patients (median
age 41 years) received bone marrow from HLA-matched unrelated
donors. Primary graft failure occurred in 2 recipients of unrelated
marrow, and was fatal in one. One patient died from VOD. Time
to neutrophil and platelet engraftment was 25 and 71 days, respec-
tively. Of the 11 patients that engrafted, 1 developed grade I, 4
developed grade II and 1 developed grade III acute GVHD. All of
them rapidly responded to standard therapy. From an overall
survival perspective, 10/13 patients are alive of which 6 are in
remission, with a median follow-up of 290 days (range 75-430).
This preliminary analysis suggests that high dose post-transplan-
tation Cy is effective as a single agent in the prophylaxis of severe
GVHD after myeloablative conditioning and HLA-matched re-
lated BMT and should be studied in patients with standard risk
hematologic malignancies.
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OUTCOME OF ALTERNATIVE DONOR TRANSPLANTATION FOR SEVERE
APLASTIC ANEMIA CAN BE COMPARABLE TO OUTCOME WITH
MATCHED RELATED DONORS
Kennedy-Nasser, A.A., Leung, K., Gottschalk, S., Lee, D.A.,
Carrum, G., Heslop, H.E., Brenner, M.K., Bollard, C.M., Krance, R.A.
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas
Children’s Hospital, The Methodist Hospital, Houston, TX.
Matched related donor (MRD) bone marrow transplantation is
the treatment of choice for pediatric patients with severe aplastic
anemia (SAA); however, only 25% of patients will have an HLA-
identical sibling. Alternative donor transplants may be an option
for these patients, but such therapies have been associated with
greater incidences of graft failures and graft-versus-host disease
(GVHD). We retrospectively analyzed 32 pediatric patients who
have undergone 34 hematopoietic stem cell transplants for severe
aplastic anemia at our institution from April 1997 to April 2005.
One patient had a MRD transplant followed by a matched unre-
lated donor (MUD) transplant, while another had an HLA-mis-
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matched unrelated donor (MMUD) transplant followed by a trans-
plant from a haplo-identical parent. Twelve patients received
MRD transplants, whereas 18 patients received alternative donor
transplants—11 MUD, 3 haplo-identical, and 4 MMUD. The
median age at transplant was 9 years (range 1.5 to 18.4 yrs). For
MRD transplants, the conditioning regimen most often utilized
cyclophosphamide 50 mg/kg  4 days and ATG 30 mg/kg  3
days. For alternative donor transplants, the conditioning regimen
most often utilized cyclophosphamide 50 mg/kg  4 days, Cam-
path 3-10 mg  4 days (dependent upon patient weight) or ATG
30 mg/kg  3 days, and TBI (single fraction 200 cGy for MUD;
two fractions 200 cGy for MMUD). Nine alternative donor recip-
ients received ATG in their preparative regimens, whereas 11
received Campath. GVHD prophylaxis was either FK506 or cy-
closporine  mini-methotrexate. The overall survival for MRD
patients was 91.7% versus 80% for alternative donor patients at a
median follow-up of 47 months (range 3 to 100 months). Of our 32
patients, there were 5 deaths: pulmonary failure with extensive,
chronic GVHD (n 1); poor graft function with infection (n 1);
and infection (n  3). For patients receiving alternative donor
transplants, the overall survival for the Campath group was 81.8%
vs. 77.8% in the ATG group. None of the Campath patients
developed extensive, chronic GVHD compared to 3/9 ATG pa-
tients. In conclusion, alternative donor transplantation using Cam-
path or ATG in the preparatory regimens offers a curative therapy
for pediatric SAA patients with survival similar to that of patients
receiving matched sibling transplants. Although follow-up is
shorter, Campath may be associated with a reduced incidence of
extensive, chronic GVHD and further investigation is warranted.
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HLA-MISMATCHED/HAPLOIDENTICAL BLOOD AND MARROW TRANS-
PLANTATION IN 207 CASES OF LEUKEMIA—REPORT FROM A SINGLE
TEAM
Lu, D.-P.1, Dong, L.1, Wu, T.1, Huang, X.-J.1, Zhang, M.-J.2,
Chen, H.1, Han, W.1, Liu, D.-H.1, Gao, Z.-Y.1, Chen, Y.-H.1,
Xu, L.-P.1, Zhang, Y.-C.1, Ren, H.-Y.1, Liu, K.-Y.1, Li, D.1 1Peking
University People’s Hospital, Dao-pei Hospital, Beijing, China; 2Medical
College of Wisconsin, Milwaukee, WI.
Objective: HLA-mismatched related donor blood and marrow
transplantation (BMT) is a suitable alternative approach in patients
who lack a matched donor. We hypothesized that differences in
BMT-outcome might be inﬂuenced by age, type of leukemia and
feto-maternal tolerance. Patients: Here is the report on outcomes
after mismatched related donor BMT for leukemia in patients aged
3-53 years, performed by a single team and transplanted from April
2002 to May 2005 and followed through June 2005. 65 (31%) had
CML, 57 (28%) AML, 73 (35%) ALL and 12 (6%) MDS. 46% had
early stage disease, 30% intermediate and 24% had advanced
disease at BMT. 32(16%) of grafts were mismatched at a single
HLA locus, 93 (45%) at 2 HLA loci and 82 (40%) at 3 HLA loci.
All patients received a uniform protocol (BuCy2  ATG) for
BMT. Results: All of patients achieved full engraftment. Rates of
acute and chronic GVHD were similar in children and adults, P 
.67 and P  .20, respectively. The two-year probabilities of TRM
were 19% and 22%, and those of relapse were 25% and 17% in
children and adults, respectively. Two-year probabilities of LFS
and overall survival (OS) were 55% and 62% in children, and 61%
and 65% in adults, respectively. The two-year OS in patients who
received graft from their mother, father, sibling and offspring were
61%, 66%, 76%, and 62% (P  .40), respectively. Disease status
was a signiﬁcant impact factor on the survival. Two years OS in
early, intermediate, and advanced stage at transplantation was
77%, 60% and 45% (P  .002), respectively. Multivariate analyses
resulted that in children with advanced leukemia and BMT with
female donor were associated with higher risks of relapse, treat-
ment failure and overall mortality. However, in adult recipients,
BMT with a cousin or father donor was associated with higher
treatment failure and overall mortality and ALL was associated
with higher relapse rates. Higher CD3 dose reduced the TRM.
Conclusion: Mismatched related BMT appears to be a feasible
option in patients who lack a matched donor. The avoidance of
female donors for children and use of sibling or maternal donor for
adults is likely to present a better survival after BMT. Graft-versus-
leukemia effect might play a role in the lower relapse rates seen in
patients with AML/CML rather than lymphoid malignancies.
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A MATCHED PAIR RETROSPECTIVE COMPARISON OF ADULT UNRE-
LATED AND SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTA-
TION (SCT) FOR AML
Dodds, A.J.1, Moore, J.1, Goh, K.Y.2, Bradstock, K.F.3, Szer, J.4,
Nivison-Smith, I.5, Ma, D.D.F.1 1St. Vincents Hospital, Sydney, NSW,
Australia; 2National University of Malaysia, Kuala Lumpur, Malaysia;
3Westmead Hospital, Sydney, NSW, Australia; 4Royal Melbourne Hos-
pital, Melbourne, Victoria, Australia; 5Australasian Bone Marrow
Transplant Recipient Registry (ABMTRR), Sydney, NSW, Australia.
Recent studies have shown nearly equivalent survival outcomes
for unrelated donor (URD) SCT in CML compared to sibling
donors. This study compared outcomes for a set of URD trans-
plants for AML and a strictly selected matching set of sibling donor
transplants. 105 adult histocompatible URD transplant recipients
with AML aged between 16 and 59 years at transplant were se-
lected from the ABMTRR database. 105 adult ﬁrst 6/6 HLA-
identical sibling transplants were selected, matched with the sub-
jects for disease stage, sex and age as a control group. There was no
signiﬁcant difference between subjects and controls in the distri-
butions of time from diagnosis to transplant, donor-recipient sex
match, prior therapies, donor age or performance status. The
transplants were carried out from 1992 to 2002 inclusive. The
median follow up of live subjects was 4.4 years and for live controls
was 6.3 years. There were 18 good risk (CR1) and 87 poor risk
(	CR1) recipients in both URD and sibling groups. Five-year
disease free survival (DFS) was not signiﬁcantly different for good-
risk URD and sibling donor recipients (62% vs 40%, P  .20), or
poor-risk URD and sibling recipients (21% vs 25%, P  .20). In a
multivariate Cox regression model, the independent risk factors for
DFS were disease stage beyond CR1 (P .001), age	49 (P .03)
and recipient CMV positivity (P  .007). Both neutrophil and
platelet engraftment were signiﬁcantly more rapid in the sibling
group but transplant related mortality at 100 days was not signif-
icantly different. There was no difference in the cumulative inci-
dence of acute GVHD grade II or above at 100 days. The cumu-
lative incidence of chronic GVHD at 1 year post transplant was
greater in good risk URD transplants compared to controls (84%
vs 61%; P .04) but not poor risk transplants. Relapse occurred in
28% of good risk URD subjects and 16% of siblings (P  .30)
while in poor risk subjects this was 39% and 29% (P  .20). Adult
URD allograft recipients for good and poor risk AML in this study
had equivalent DFS probability to sibling recipients. This study
provides a rationale for a larger prospective study of risk factors in
allogeneic transplantation for AML. The ABMTRR is an impor-
tant national data resource providing a large and readily accessible
sample frame for retrospective studies.
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NEW TREATMENT MODALITY BY ADOPTIVE TRANSFER OF CHIMERIC
CELLS FROM TWO DIFFERENT MHC MISMATCHED DONORS
Siemionow, M., Klimczak, A., Agaoglu, G., Jankowska, A., Kulahci, Y.
The Cleveland Clinic Foundation, Cleveland, OH.
Background: Donor bone marrow transplantation (BMT) may
promote chimerism in solid organ and composite tissue allografts.
This study was designed to evaluate the rationale of immunother-
apy with adoptive transfer of donor-speciﬁc cells originated from
two different MHC mismatched donors and transplanted to the
same recipients. Methods: Seven primary trimera were created
across the MHC barrier from LBN (RT1n) (n  7) and ACI
(RT1a) (n  7) donors to LEW (RT1l) recipients (n  7), under a
7-day protocol of 
-TCRmAb/CsA therapy. Bilateral intraosse-
ous BMT (70 106) was performed from LBN and ACI donors to
left and right femur respectively. Fourteen secondary trimeras
were created via adoptive transfer of MACS-sorted primary chi-
meric cells: double positive RT1n/RT1a cells (9.0  106 to 24.0 
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